Market regulator Sebi has issued a warning letter to Aurobindo Pharma for disclosing “very limited and restricted information” to the inventory exchanges about an USFDA audit of the corporate’s energetic pharmaceutical substances manufacturing facility (API) in Hyderabad. “The only fact disclosed was that a warning letter was received from the U.S. FDA. The company did not disclose details on the reason and the non-compliance/aberration observed,” SEBI stated. The disclosure shouldn’t be consistent with rules governing disclosures and obligations of listed entities, it stated.
“You are hereby warned and advised to ensure compliance with all applicable provisions of SEBI Regulations. Any such aberration in future would be viewed seriously and appropriate action would be initiated,” the regulator stated within the letter. The firm stated the SEBI communication pertains to sure disclosures made on the continued USFDA audit of firm’s Unit-1 and observations made by the USFDA between 2019 to 2022.
Express Subscription
Do not hit the wall, subscribe for the perfect protection out of India beginning at simply $5 per thirty days
